<DOC>
	<DOCNO>NCT00004108</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treating patient liver cancer .</brief_summary>
	<brief_title>DX-8951f Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antitumor activity DX-8951f term antitumor response , response duration , survival patient hepatocellular carcinoma . II . Assess quantitative qualitative toxicity treatment regimen patient population . III . Evaluate pharmacokinetics DX-8951 plasma . OUTLINE : Patients receive DX-8951f IV 30 minute daily 5 day . Treatment repeat every 3 week least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month survival . PROJECTED ACCRUAL : A total 12-37 patient accrue study 12 month .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hepatocellular carcinoma without evidence unresectable extrahepatic metastasis Previously untreated disease OR Progressive disease first line chemotherapy Bidimensionally measurable disease CT scan , chest xray , MRI abdomen No brain metastases PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 80,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL Albumin least 2.8 g/dL SGOT/SGPT great 5 time upper limit normal ( ULN ) PT/INR great 1.5 time ULN coumadin therapy Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : No concurrent serious infection No life threaten illness No overt psychosis mental disability would preclude informed consent No malignancy within past 5 year except curatively treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month prior study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No prior camptothecin analogues No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 4 week since prior major surgery recover No concurrent surgery Other : No concurrent anticancer therapy At least 4 week since prior investigational drug ( include analgesic antiemetic ) No investigational drug within 28 day final dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>